Emerging studies suggest Retatrutide , a dual agonist targeting both incretin and GIP , may offer a notable step forward for body management . Preliminary human tests have demonstrated impressive reductions in body fat , potentially outperforming current weight-loss medications . Nevertheless , additional study is needed to thoroughly understand it